Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)

Enrica Marchi, Jeffrey W. Craig, Matko Kalac

Blood (2024) 144 (18): 1898–1909.

https://doi.org/10.1182/blood.2023021788

Published: 2024

Includes: Supplemental data

Journal Articles

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Waleed Alduaij, Aixiang Jiang, Diego Villa, Brett J Collinge, Susana Ben-Neriah, Merrill Boyle, Barbara Meissner, Laura K Hilton, Pedro Farinha, Graham W. Slack, Jeffrey W Craig, Alina S. Gerrie, Ciara L Freeman, Andrew J Mungall, Christian Steidl, Laurie H. Sehn, David W. Scott, Kerry J. Savage

Blood blood.2024025725.

https://doi.org/10.1182/blood.2024025725

Published: 2024

Includes: Supplemental data

Journal Articles

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Brett Collinge, Susana Ben-Neriah, Laura K. Hilton, Waleed Alduaij, Tracy Tucker, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Merrill Boyle, Barbara Meissner, Diego Villa, Alina S. Gerrie, Laurie H. Sehn, Kerry J. Savage, Ryan D. Morin, Andrew J. Mungall, Christian Steidl, David W. Scott

Blood (2024) 144 (15): 1611–1616.

https://doi.org/10.1182/blood.2024025603

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

Blood (2023) 141 (20): 2493–2507.

https://doi.org/10.1182/blood.2022018248

Published: 2023

Includes: Supplemental data

Journal Articles

Long-Term Outcomes of Patients Aged 65 Years or Older with Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) and T-Follicular Helper T-Cell Lymphoma (TFHTCL) Treated with Curative Intent CHOP(like) Chemotherapy

Henry S. Ngu, Diego Villa, Alina S. Gerrie, Christopher P. Venner, Andrew Lytle, Brian Skinnider, Jeffrey W. Craig, Graham W. Slack, David W. Scott, Laurie H. Sehn, Kerry J. Savage

Blood (2022) 140 (Supplement 1): 3713–3715.

https://doi.org/10.1182/blood-2022-168586

Published: 2022

Journal Articles

Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia

Waleed Alduaij, Aixiang Jiang, Diego Villa, Brett Collinge, Susana Ben-Neriah, Merrill Boyle, Barbara Meissner, Laura K Hilton, Pedro Farinha, Graham W Slack, Jeffrey W. Craig, Alina S. Gerrie, Ciara L. Freeman, Andrew J. Mungall, Christian Steidl, Laurie H. Sehn, David W. Scott, Kerry J. Savage

Blood (2022) 140 (Supplement 1): 1332–1333.

https://doi.org/10.1182/blood-2022-159356

Published: 2022

Journal Articles

Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL

Blood (2022) 140 (Supplement 1): 1310–1312.

https://doi.org/10.1182/blood-2022-160187

Published: 2022

Journal Articles

Integrated Single Cell Analysis Reveals Co-Evolution of Malignant B Cells and the Tumor Microenvironment in Transformed Follicular Lymphoma

Clementine Sarkozy, Shaocheng Wu, Katsuyoshi Takata, Tomohiro Aoki, Susana Ben-Neriah, Katy Milne, Brad H Nelson, Andrew P. Weng, David W. Scott, Jeffrey W. Craig, Christian Steidl, Andrew Roth

Blood (2022) 140 (Supplement 1): 750–751.

https://doi.org/10.1182/blood-2022-160405

Published: 2022

Journal Articles

Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?

Brett Collinge, Susana Ben-Neriah, Laura K Hilton, Waleed Alduaij, Tracy Tucker, Graham W Slack, Pedro Farinha, Jeffrey W. Craig, Merrill Boyle, Barbara Meissner, Kelly Mekwunye, Diego Villa, Alina S. Gerrie, Laurie H. Sehn, Kerry J. Savage, Ryan D. Morin, Andrew J. Mungall, Christian Steidl, David W. Scott

Blood (2022) 140 (Supplement 1): 9244–9246.

https://doi.org/10.1182/blood-2022-170065

Published: 2022

Journal Articles

Genetic Determinants of Isolated and Systemic Testicular Diffuse Large B-Cell Lymphoma Highlight a Disease Spectrum

Blood (2022) 140 (Supplement 1): 6374–6375.

https://doi.org/10.1182/blood-2022-165546

Published: 2022

Journal Articles

Frontline Therapy with Bendamustine-Rituximab (BR) in Patients with Treatment-Naïve Waldenstrom's Macroglobulinemia Confers Similar Long-Term Outcomes to R-CVP in a Real-World Setting: A Population-Based Analysis

Jowon Laura Kim, Alina S. Gerrie, Kerry J. Savage, Diego Villa, David W. Scott, Jeffrey W Craig, Pedro Farinha, Brian Skinnider, Graham W. Slack, Joseph M. Connors, Laurie H. Sehn, Ciara L. Freeman

Blood (2021) 138 (Supplement 1): 1353.

https://doi.org/10.1182/blood-2021-146738

Published: 2021

Journal Articles

Population-Wide Introduction of Dose-Adjusted EPOCH-R Is Associated with Improved Outcome of High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements with Diffuse Large B-Cell Lymphoma Morphology

Blood (2021) 138 (Supplement 1): 1458.

https://doi.org/10.1182/blood-2021-145954

Published: 2021

Journal Articles

Single-Cell Profiling Reveals Clinically Relevant Evolutionary Trajectories and Alternate Biologies in Human Follicular Lymphoma

Blood (2021) 138 (Supplement 1): 450.

https://doi.org/10.1182/blood-2021-153237

Published: 2021

Journal Articles

Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification

Michael Nissen, Xuehai Wang, Clementine Sarkozy, Aixiang Jiang, Daisuke Ennishi, Tomohiro Aoki, Stacy Hung, Elizabeth Chavez, Jeffrey W Craig, Pedro Farinha, Graham W. Slack, David W. Scott, Christian Steidl, Andrew P. Weng

Blood (2021) 138 (Supplement 1): 719.

https://doi.org/10.1182/blood-2021-154082

Published: 2021

Journal Articles

Characterization of DLBCL with a PMBL gene expression signature

Blood (2021) 138 (2): 136–148.

https://doi.org/10.1182/blood.2020007683

Published: 2021

Includes: Supplemental data

Journal Articles

The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC

Blood (2021) 137 (16): 2196–2208.

https://doi.org/10.1182/blood.2020007193

Published: 2021

Includes: Supplemental data

Journal Articles

Rituximab Monotherapy Compared to Observation in Patients with Newly Diagnosed Asymptomatic Advanced Stage Follicular Lymphoma: A Retrospective Population-Based Analysis

Sarah E. Perry, MD MSc, Derrick G. Lee, PhD, Ciara L. Freeman, MSc, MBBChir, Diego Villa, MDMPH, Alina S. Gerrie, MD MPH, Pedro Farinha, MD PhD, Jeffrey W. Craig, MD PhD, Graham W. Slack, MD, Joseph M. Connors, MD, David W. Scott, MBChB, PhD, Kerry J. Savage, BSc, MD MSc, Laurie H. Sehn, MDMPH

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136457

Published: 2020

Journal Articles

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Pedro Farinha, MD PhD, Daisuke Ennishi, MD PhD, Anja Mottok, MD PhD, Susana Ben-Neriah, BSc, Barbara Meissner, PhD, Merrill Boyle, BSc, Jeffrey W. Craig, MD PhD, Graham W Slack, MD, Diego Villa, MD MPH, Kerry J Savage, BSc, MD MSc, Laurie H Sehn, MD, Ryan D. Morin, PhD, Marco A. Marra, PhD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Christian Steidl, MD, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 3964.

https://doi.org/10.1182/blood-2019-121943

Published: 2019

Journal Articles

Assessment of CD52 Expression in "Double-Hit" and "Double-Expressor" Lymphomas: Implications for Clinical Trial Eligibility

Jeffrey W. Craig, MD PhD, Michael J. Mina, MD PhD, Jennifer Crombie, MD, Ann S LaCasce, MD MSc, David M. Weinstock, MD, Geraldine S. Pinkus, Olga Pozdnyakova, MD PhD

Blood (2017) 130 (Supplement 1): 4035.

https://doi.org/10.1182/blood.V130.Suppl_1.4035.4035

Published: 2017

Journal Articles

Systematic KIT Sequencing Identifies Unsuspected Systemic Mastocytosis with Associated Hematological Neoplasm

Elizabeth A Morgan, MD, Jeffrey W. Craig, MD PhD, Annette S. Kim, MDPhD, Geraldine S. Pinkus, Jon C. Aster, MD PhD, Frank C Kuo, MBBS, PhD, David P. Steensma, MD, R. Coleman Lindsley, MD PhD, Daniel J. DeAngelo, MD

Blood (2017) 130 (Supplement 1): 2923.

https://doi.org/10.1182/blood.V130.Suppl_1.2923.2923

Published: 2017

NARROW

Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

Long-Term Outcomes of Patients Aged 65 Years or Older with Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) and T-Follicular Helper T-Cell Lymphoma (TFHTCL) Treated with Curative Intent CHOP(like) Chemotherapy

Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia

Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL

Integrated Single Cell Analysis Reveals Co-Evolution of Malignant B Cells and the Tumor Microenvironment in Transformed Follicular Lymphoma

Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?

Genetic Determinants of Isolated and Systemic Testicular Diffuse Large B-Cell Lymphoma Highlight a Disease Spectrum

Frontline Therapy with Bendamustine-Rituximab (BR) in Patients with Treatment-Naïve Waldenstrom's Macroglobulinemia Confers Similar Long-Term Outcomes to R-CVP in a Real-World Setting: A Population-Based Analysis

Population-Wide Introduction of Dose-Adjusted EPOCH-R Is Associated with Improved Outcome of High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements with Diffuse Large B-Cell Lymphoma Morphology

Single-Cell Profiling Reveals Clinically Relevant Evolutionary Trajectories and Alternate Biologies in Human Follicular Lymphoma

Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification

Characterization of DLBCL with a PMBL gene expression signature

The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC

Rituximab Monotherapy Compared to Observation in Patients with Newly Diagnosed Asymptomatic Advanced Stage Follicular Lymphoma: A Retrospective Population-Based Analysis

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Assessment of CD52 Expression in "Double-Hit" and "Double-Expressor" Lymphomas: Implications for Clinical Trial Eligibility

Systematic KIT Sequencing Identifies Unsuspected Systemic Mastocytosis with Associated Hematological Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only